Fumaric acid esters in psoriasis and multiple sclerosis

Summary Fumaric acid esters (FAEs) are effective in patients with moderate to severe psoriasis. Recent studies also report the efficacy of one FAE component, dimethylfumarate, in relapsing forms of multiple sclerosis (MS). We describe the case of a patient with MS who developed severe plaque psorias...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental dermatology 2014-06, Vol.39 (4), p.488-491
Main Authors: Zecca, C., Caporro, M., Adami, M., Mainetti, C., Gobbi, C.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - adverse effects
Drug Eruptions - drug therapy
Esters
Fumarates - therapeutic use
Humans
Immunosuppressive Agents
Interferon beta-1a
Interferon-beta - adverse effects
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Psoriasis - chemically induced
Psoriasis - drug therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Fumaric acid esters (FAEs) are effective in patients with moderate to severe psoriasis. Recent studies also report the efficacy of one FAE component, dimethylfumarate, in relapsing forms of multiple sclerosis (MS). We describe the case of a patient with MS who developed severe plaque psoriasis during interferon‐β‐1a treatment for MS. The psoriasis was unresponsive to usual topical treatments and phototherapy. The patient was started on FAE 720 mg daily, with complete remission of the psoriatic lesions and neurological stabilization at follow‐up at 24 months. Our case suggests that FAEs could represent a therapeutic option for patients with MS who develop plaque psoriasis following exposure to immune‐modulating agents.
ISSN:0307-6938
1365-2230
DOI:10.1111/ced.12326